Your browser doesn't support javascript.
loading
Photon-based high-dose single-fraction radiosurgery, an effective treatment modality for recurrent uveal melanoma.
Laliscia, Concetta; Genovesi-Ebert, Federica; Perrone, Franco; Fuentes, Taiusha; Cresti, Federica; Guido, Francesca; Tripodi, Maria; Paiar, Fabiola.
Afiliação
  • Laliscia C; Department of New Technologies and Translational Research, Division of Radiation Oncology, University Hospital of Pisa, Pisa, Italy.
  • Genovesi-Ebert F; Department of Ophthalmic Surgery, Division of Ophthalmic Surgery, University Hospital of Pisa, Pisa, Italy.
  • Perrone F; Department of Medical Physics, Division of Medical Physics, University Hospital of Pisa, Pisa, Italy.
  • Fuentes T; Department of New Technologies and Translational Research, Division of Radiation Oncology, University Hospital of Pisa, Pisa, Italy.
  • Cresti F; Department of Ophthalmic Surgery, Division of Ophthalmic Surgery, University Hospital of Pisa, Pisa, Italy.
  • Guido F; Department of Ophthalmic Surgery, Division of Ophthalmic Surgery, University Hospital of Pisa, Pisa, Italy.
  • Tripodi M; Department of Medical Physics, Division of Medical Physics, University Hospital of Pisa, Pisa, Italy.
  • Paiar F; Department of New Technologies and Translational Research, Division of Radiation Oncology, University Hospital of Pisa, Pisa, Italy.
Contemp Oncol (Pozn) ; 27(2): 109-112, 2023.
Article em En | MEDLINE | ID: mdl-37794987
ABSTRACT

Introduction:

To evaluate and report the outcome of a patient with locally recurrent uveal melanoma (UM) previously treated with brachytherapy (BT), using a second personalized globe-sparing radiotherapy approach. Material and

methods:

In June 2020, a 78-year-old man arrived at our institution with diplopia and suspected uveal melanoma. At the ophthalmological evaluation (B-scan and A-scan ultrasonography) a lesion in the right eye at 6-7 hours of about 5 mm thickness, with internal lacunar areas, approximately 7 mm away from the limbus, was observed. The patient underwent ruthenium plaque BT at a total dose of 110 Gy prescribed to the apex of the tumour. At the follow-up, the lesion was under control until September 2021, but it recurred with a satellite exudative detachment in the lower and temporal sectors 7-10 hours. At the B-scan the lesion had a maximum thickness of 4.6 mm. Subsequently, in a multidisciplinary discussion, one single fraction stereotactic radiosurgery was scheduled. The prescribed dose was 27 Gy in the de-novo lesion and 24 Gy in the previously irradiated site. Stereotactic radiosurgery was performed in October 2021.

Results:

The time interval between the 2 treatments was 15 months. Twenty months after recurrence, local tumour control was observed, and no metastases were detected on follow-up examinations. No severe acute or late toxicity was observed due to the retreatment.

Conclusions:

Photon stereotactic radiotherapy is a feasible, acceptably tolerated modality, and it represents an eye-preserving treatment also for patients with recurrent UM unfit for BT.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Contemp Oncol (Pozn) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Contemp Oncol (Pozn) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália